Over 1,000 Cardiac Patients Treated with Genesis Robotic System
Retrieved on:
Thursday, April 13, 2023
ST. LOUIS, April 13, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that over 1,000 cardiac arrhythmia patients have been treated using the Genesis Robotic Magnetic Navigation (RMN) system.
Key Points:
- ST. LOUIS, April 13, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that over 1,000 cardiac arrhythmia patients have been treated using the Genesis Robotic Magnetic Navigation (RMN) system.
- Since then, physicians at eight global hospitals have treated over 1,000 patients using Genesis RMN.
- The Genesis RMN system introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias.
- Physicians have used Genesis RMN to treat a broad spectrum of arrhythmia patients, including the underserved community of patients with complex cardiac disease that cannot be treated well or at all without Stereotaxis’ robotic technology.